Sai Parenteral Files for IPO: Key Details and Risks Revealed in Registration Statement

Sai Parenteral IPO Report

Initial Public Offering (IPO) Details

• IPO Size: ₹408.79 crore
• IPO Period: March 24 - March 27
• Fresh Issue: ₹285 crore (0.73 crore shares)
• Offer for Sale (OFS): ₹123.79 crore (0.32 crore shares)

Objectives of the Offer

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

• Expand and upgrade manufacturing facilities
• Establish a new R&D centre
• Repay debt
• Meet working capital requirements
• General corporate purposes

Selling Shareholders

• Vikasa India EIF I Fund
• Tilokchand Punamchand Ostwal
• Bhanwar Lal Chandak
• Devendra Chawla
• Sreelekha Ganta
• Ashish Maheshwari
• Vijay Gondi
• Padma Guntupalli
• Nilesh Pravinchandra Doshi
• Bhautik Mukund Shah

Listing Details

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

• Listing on both BSE and NSE

Company Overview

• Sai Parenteral: A diversified pharmaceutical formulations company with capabilities in research, development, and manufacturing
• Business Segments: Branded generics, contract development and manufacturing organisation (CDMO) products and services
• Therapeutic Areas: Cardiovascular, anti-diabetic, neuropsychiatry, respiratory, antibiotics, vitamins, minerals and supplements (VMS), gastroenterology, analgesics, and dermatology

Financial Performance

• Six-Month Period Ended September 2025: Profit of ₹7.7 crore, revenue of ₹86.9 crore
• Financial Year Ended March 2025: Profit of ₹14.4 crore (71.8% increase), revenue of ₹163.1 crore (6% increase)

Global Industry Overview

• Global Pharmaceutical Market: Estimated at $1.8 trillion in 2025, projected to grow to $2.9 trillion by 2033 with a CAGR of 5.9%

Risk Factors

• 44.78%, 47.64%, and 92.03% of net revenue during Fiscals 2025, 2024, and 2023 derived from injectable sales, which may affect business and financial performance

Subsidiaries

• Five subsidiaries, including Indian and foreign subsidiaries, and step-down foreign subsidiaries

Lead Managers and Registrar

• Arihant Capital Markets Ltd.: Book-running lead manager
• Bigshare Services: Registrar of the issue